Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874908 | 0.91 | ACP3 (0.56) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9341168 | 0.87 | LTA4H (0.59) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28806943 | 0.85 | ALDH1A1 (0.51) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL9318733 | 0.84 | CA1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9165325 | 0.84 | MAOA (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL365643 | 0.82 | TDP1 (0.56) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7768379 | 0.80 | TDP1 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4810833 | 0.80 | TDP1 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11602455 | 0.78 | MAPK1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL14622110 | 0.78 | ALDH1A1 (0.43) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7989649-B2 | Tumor imaging compounds | EMORY UNIVERSITY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2110380-B1 | Alpha-N-methylation of amino acids | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-1499584-B1 | TUMOR IMAGING COMPOUNDS | UNIV EMORY (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090264620-A1 | N-Methylation of amino acids | ROCHE PALO ALTO LLC | 2009-10-22 | — | — | US | disclosed |
| EP-2110380-A1 | Alpha-N-methylation of amino acids | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | EMORY UNIVERSITY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-5175164-A | Hypotensive agents | MERCK & CO., INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0517357-A1 | Angiotensin II antagonists incorporating a substituted indole or dihydroindole | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0515535-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| EP-0512676-A1 | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-5162325-A | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1991012001-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| US-4188226-A | OXIDIZER, REDUCER, HALOGENATED CARBOCYCLIC COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-02-12 | — | — | US | disclosed |
| US-4118561-A | ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-3937699-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-02-10 | — | — | US | disclosed |
| US-3936491-A | Adamantylene compounds | U.S. PHILIPS CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | AADAT, MKI67, SSTR1 | CA1 113/4885CA2 1048/4885CA7 336/4885 |
| US-20090264620-A1 | N-Methylation of amino acids | MGMT, NNMT, PRMT1 | CA1 2276/4885CA2 4131/4885CA7 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.